Soluble endoglin in the pathogenesis of preeclampsia: investigation of mechanisms and the development of therapeutics

可溶性内皮糖蛋白在先兆子痫发病机制中的作用：机制研究和治疗方法的开发

• 批准号: nhmrc : 1048707
• 负责人: Dr Tu'Uhevaha Kaitu'U-Lino
• 金额: $ 38.19万
• 依托单位: The University of Melbourne
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2013
• 资助国家: 澳大利亚
• 起止时间: 2013-01-01 至 2015-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/soluble-endoglin-pathogenesis-development-therapeutics/112032
• 关键词: Soluble; endoglin; pathogenesis; preeclampsia; investigation

Preeclampsia is a severe disease of pregnancy. As the pathogenesis is poorly understood, the only treatment is for clinicians to deliver babies irrespective of gestation. We have identified MMP-14 as the molecular scissors that release soluble endoglin from placenta, a toxin centrally responsible for severe preeclampsia. In this project we aim to further investigate the mechanisms governing soluble endoglin release and to begin developing a potential therapeutic for use in the clinic.

子痫前期是一种严重的妊娠期疾病。由于发病机制尚不清楚，唯一的治疗方法是临床医生无论怀孕与否都要接生。我们已经确认，基质金属蛋白酶-14是一种分子剪刀，可以从胎盘中释放出可溶性的endoglin，这是一种对严重子痫前期负有主要责任的毒素。在这个项目中，我们的目标是进一步研究控制可溶性endoglin释放的机制，并开始开发一种潜在的临床治疗方法。